Cargando…
Therapeutic time window for conivaptan treatment against stroke-evoked brain edema and blood-brain barrier disruption in mice
BACKGROUND: Ischemic stroke is often complicated by brain edema, disruption of blood-brain barrier (BBB), and uncontrolled release of arginine-vasopressin (AVP). Conivaptan, a V1a and V2 receptor antagonist, reduces brain edema and minimizes damage to the blood-brain barrier after stroke. Most strok...
Autores principales: | Zeynalov, Emil, Jones, Susan M., Elliott, J. Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576654/ https://www.ncbi.nlm.nih.gov/pubmed/28854286 http://dx.doi.org/10.1371/journal.pone.0183985 |
Ejemplares similares
-
Arginine-Vasopressin Receptor Blocker Conivaptan Reduces Brain Edema and Blood-Brain Barrier Disruption after Experimental Stroke in Mice
por: Zeynalov, Emil, et al.
Publicado: (2015) -
Recent advances and future directions in preclinical research of arginine-vasopressin (AVP) receptor blocker conivaptan in the context of stroke
por: Zeynalov, Emil, et al.
Publicado: (2016) -
Transcellular blood–brain barrier disruption in malaria-induced reversible brain edema
por: Jin, Jessica, et al.
Publicado: (2022) -
Lycium barbarum Extracts Protect the Brain from Blood-Brain Barrier Disruption and Cerebral Edema in Experimental Stroke
por: Yang, Di, et al.
Publicado: (2012) -
Conivaptan: Evidence supporting its therapeutic use in hyponatremia
por: Li-Ng, Melissa, et al.
Publicado: (2010)